Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced it has received an additional $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) — the second-largest public cancer research funder globally.
This latest payment is part of Plus Therapeutics’ previously awarded $17.6 million grant from CPRIT and represents the second round of non-dilutive financing, following the $1.6 million advance received in July 2025. These funds will continue to support the company’s development of novel radiotherapeutics aimed at transforming the treatment of central nervous system (CNS) cancers, including leptomeningeal metastases (LM) and other aggressive brain and spinal tumors.
“We are grateful for CPRIT’s continued support as we advance our targeted radiotherapeutics pipeline,” said Marc Hedrick, M.D., President and CEO of Plus Therapeutics. “Non-dilutive funding from leading organizations like CPRIT enables us to accelerate innovation while preserving shareholder value.”
Accelerating Innovation in Targeted Radiotherapeutics
Plus Therapeutics is pioneering targeted radiotherapeutics — therapies that precisely deliver radiation directly to tumor sites while sparing surrounding healthy tissue. The company’s research and development focus includes treatments for:
-
Leptomeningeal metastases (LM): A severe complication of advanced cancers that spread to the brain and spine.
-
Difficult-to-treat CNS tumors: Innovative delivery systems are designed to improve precision, reduce toxicity, and enhance patient outcomes.
By leveraging convection-enhanced delivery (CED) and advanced isotope technology, Plus Therapeutics aims to redefine how radiation therapy is administered for challenging cancers.
About CPRIT
The Cancer Prevention and Research Institute of Texas (CPRIT) is the second-largest public funder of cancer research worldwide. Through its grants, CPRIT supports groundbreaking discoveries in cancer prevention, early detection, and treatment — helping companies like Plus Therapeutics bring innovative therapies to patients faster.
Learn More
Read the full press release: Plus Therapeutics CPRIT Advance Payment Announcement
About Plus Therapeutics (Nasdaq: PSTV): Visit Investor Relations
Learn about our clinical trials: Respect Trials
#PlusTherapeutics #PSTV #Radiotherapeutics #CancerResearch #LeptomeningealCancer #CNSCancers #NonDilutiveFunding #HealthcareInnovation #Radiotherapeutic #CPRIT
Recent Comments